Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46
From version 25.1
edited by manuelmenendez
on 2025/01/29 18:47
Change comment: There is no comment for this version
To version 4.1
edited by manuelmenendez
on 2025/01/27 22:53
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,10 +2,9 @@
2 2  (((
3 3  (% class="container" %)
4 4  (((
5 -= //A new tridimensional diagnostic framework for CNS diseases// =
5 += My Collab's Extended Title =
6 6  
7 -This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies.
8 -We aim to create a structured, interpretable, and scalable diagnostic tool.
7 +My collab's subtitle
9 9  )))
10 10  )))
11 11  
... ... @@ -13,76 +13,18 @@
13 13  (((
14 14  (% class="col-xs-12 col-sm-8" %)
15 15  (((
16 -= What is this about and what can I find here? =
15 += What can I find here? =
17 17  
18 -== **Overview** ==
17 +* Notice how the table of contents on the right
18 +* is automatically updated
19 +* to hold this page's headers
19 19  
20 -The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on:
21 += Who has access? =
21 21  
22 -* **Axis 1**: Etiology (genetic or other causes of diseases).
23 -* **Axis 2**: Molecular Markers (biomarkers).
24 -* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
25 -
26 -
27 -This methodology enables:
28 -
29 -* Greater precision in diagnosis.
30 -* Integration of incomplete datasets using AI-driven probabilistic modeling.
31 -* Stratification of patients for personalized treatment.
32 -
33 -== **The case of neurodegenerative diseases** ==
34 -
35 -There have been described these 3 diagnostic axes:
36 -
37 -[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
38 -
39 -* (((
40 -**Axis 1: Etiology**
41 -
42 -* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers.
43 -* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression.
44 -* //Tests//: Genetic testing, lifestyle, and cardiovascular screening.
23 +Describe the audience of this collab.
45 45  )))
46 -* (((
47 -**Axis 2: Molecular Markers**
48 48  
49 -* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression.
50 -* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology.
51 -* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET).
52 -)))
53 -* (((
54 -**Axis 3: Neuroanatomoclinical**
55 55  
56 -* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments.
57 -* //Examples//: Hippocampal atrophy correlating with memory deficits.
58 -* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations.
59 -)))
60 -
61 -== **Applications** ==
62 -
63 -This system enhances:
64 -
65 -* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
66 -* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
67 -
68 -== Who has access? ==
69 -
70 -We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
71 -
72 -== How to Contribute ==
73 -
74 -* Access the `/docs` folder for guidelines.
75 -* Use `/code` for the latest AI pipelines.
76 -* Share feedback and ideas in the wiki discussion pages.
77 -
78 -== Key Objectives ==
79 -
80 -* Develop interpretable AI models for diagnosis and progression tracking.
81 -* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
82 -* Foster collaboration among neuroscientists, AI researchers, and clinicians.
83 -)))
84 -
85 -
86 86  (% class="col-xs-12 col-sm-4" %)
87 87  (((
88 88  {{box title="**Contents**"}}
... ... @@ -89,14 +89,6 @@
89 89  {{toc/}}
90 90  {{/box}}
91 91  
92 -== Main contents ==
93 -
94 -* `/docs`: Documentation and contribution guidelines.
95 -* `/code`: Machine learning pipelines and scripts.
96 -* `/data`: Sample datasets for testing.
97 -* `/outputs`: Generated models, visualizations, and reports.
98 -* [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]]
99 -* [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]]
100 -* [[to-do-list>>to-do-list]]
33 +
101 101  )))
102 102  )))
tridimensional.png
Author
... ... @@ -1,1 +1,0 @@
1 -XWiki.manuelmenendez
Size
... ... @@ -1,1 +1,0 @@
1 -149.8 KB
Content
Collaboratory.Apps.Collab.Code.CollabClass[0]
Public
... ... @@ -1,1 +1,1 @@
1 -Yes
1 +No
XWiki.XWikiRights[3]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Levels
... ... @@ -1,1 +1,0 @@
1 -view
Users
... ... @@ -1,1 +1,0 @@
1 -XWiki.XWikiGuest
XWiki.XWikiRights[4]
Allow/Deny
... ... @@ -1,1 +1,0 @@
1 -Allow
Groups
... ... @@ -1,1 +1,0 @@
1 -XWiki.XWikiAllGroup
Levels
... ... @@ -1,1 +1,0 @@
1 -view